Podcast Episodes

Back to Search
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

7 years, 9 months ago

Short Long
View Episode
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

7 years, 9 months ago

Short Long
View Episode
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

7 years, 10 months ago

Short Long
View Episode
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

7 years, 10 months ago

Short Long
View Episode
Episode 38: Your guide to the #CRISPRbabies controversy
Episode 38: Your guide to the #CRISPRbabies controversy

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?

7 years, 10 months ago

Short Long
View Episode
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

7 years, 11 months ago

Short Long
View Episode
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug

Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

7 years, 11 months ago

Short Long
View Episode
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence

Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?

7 years, 11 months ago

Short Long
View Episode
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma

Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?

7 years, 11 months ago

Short Long
View Episode
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

8 years ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us